Studies of viral dynamics are important to our understanding of the pathogenesis of HIV-1 infection and in assessment of the potency of antiretroviral therapies. Although many different viral dynamic models and methods for estimating viral dynamic parameters have been proposed and used in various studies, none has been entirely satisfactory. We propose here a segmental model to describe the viral load, and estimate the dynamic parameters by using a mixed-effects model. We address the relation between the baseline viral load and the decay rate of the first phase of viral load decay, and divide patients into three categories on the basis of their changing viral load patterns.
Introduction
In clinical studies of the efficacy of anti-HIV drugs, the changing viral load in subjects' blood can be approximated by an exponential function within the first two weeks after starting the treatment. In other words, the log of the viral load decreases linearly and sharply with time (i.e., has a large negative slope). 1, 2 After the first two weeks, however, the picture is very different and shows multiple phases of decline and increase. Within the first 2-3 months but after the first two weeks, the relation between the log of the viral load and time remains linear, but the curve is flat (i.e., horizontal) while the virus is released by macrophages and other long-lived infected cells. 3 At some time between the third and eighth month, the viral load in some individuals increases sharply and reaches the level measured before treatment, presumably because of the development of resistance of the virus to the drugs.
In studying viral dynamics to understand the pathogenesis of HIV-1 infection and to assess the potency of antiretroviral therapies, viral load decay rates have been estimated by using linear models in a log 10 scale in short-term (about one week) dynamics 1, 2, [4] [5] [6] [7] and biphasic models (nonlinear biexponential model) in longer-term (2-8 weeks) dynamics. 3, [8] [9] [10] [11] Wu et al. 12 compared linear and biphasic nonlinear modeling and found that linear modeling may result in misleading conclusions because one has to truncate the data, but it is not clear where the data should be cut. The biphasic nonlinear modeling 12 showed promise. However, implementation of the biphasic nonlinear modeling becomes a challenge because the computation is very sensitive to initial values and convergence problems often occur. We propose here a piecewise-linear segmental model as a compromise. This model does not require truncation of data and is more easily implemented than the biphasic nonlinear model.
Model and methods
ACTG 315 13 was developed by the Immunology Research Agenda Committee of the US NIAID-sponsored ACTG. The protocol was conducted at several university hospitals such as Case Western Reserve University Lukes Medical Center and the University of Colorado Health Sciences Center. Figure 1 presents data from the ACTG 315 study, as a scatter plot of viral load (in log 10 scale) on treatment days 0, 2, 7, 10, 14, 28, 56, 84, 168 and 336. Figure 1 shows that the viral load in most patients declines rapidly within the first two weeks and the curve has a large negative slope; after two weeks, however, the trend of decline decreases and the curve becomes flat. At about 10 weeks, the viral loads rebound, and most increase until the end of treatment. To better understand HIV pathogenesis and to improve treatment management and care of patients with AIDS, it is important to identify when a patient's viral load declines and when the change to a slower decline and rebound occur. Figure 1 shows that we may describe the effect of treatment on viral load in three patterns ( Figure 2 ): rapid decline followed by slow decline and rebound; rapid decline followed by slow decline; and decline followed by rebound. Rapid decline followed by slow decline [ Figure 2 (b)] indicates that drug resistance does not develop, and the treatment can be thought successful. We are interested in the rates of decline and rebound and the time-points at which changes occur. From the biological perspective, one may link the first change point to the time at which the macrophages or other long-lived HIV-infected cells from lymphoid tissues release free HIV into the blood; 3 one may link the second change point to the time at which the virus has developed drug resistance. These time points have important clinical implications: they signal the time to change drugs to avoid the problem of drug resistance.
Model
We use a unified function to describe the patterns in Figure 2 . The form for (a) is derived first because (b) and (c) are its special cases. Let t L and t R denote the times of the first and second change points, respectively. The first segment of the curve is described by η 0 + η 1 t, represents a rapid decline in viral load after treatment. η 0 represents baseline viral load and η 1 represents the rate of viral load change. The second line is described by η 2 + η 3 t, and represents a less rapid decline after some unknown time point t L . This slower decline occurs as a result of the release of HIV from macrophages or other longlived cells from the lymphoid tissues. The third segment is described by η 4 + η 5 t and represents an increase in the viral load after some unknown time point t R as a result of drug resistance. Notice that the first two segments agree at t L , whereas the last two segments agree at t R . Denote 1 = η 3 − η 1 and 2 = η 5 − η 3 . By combining the three segments, we can describe the pattern of (a) in Figure 2 by the form where s + denotes max(s, 0) for a variable s. When η 1 < 0, η 1 + 1 < 0 and η 1 + 1 + 2 > 0, (1) represents (a); when η 1 < 0, η 1 + 1 < 0 and 2 = 0, (1) represents (b) and when η 1 < 0, η 1 + 2 > 0 and 1 = 0, (1) represents (c).
Suppose that there are n HIV-infected individuals. Let y ij be the viral load log 10 (RNA) of the ith patient at time t ij . Because of between-subject and within-subject variations, the parameters η 0 , η 1 , 1 , 2 , t L and t R vary with respect to different patients. We model log 10 (RNA) by the mixed-effects model: 14
where ε ij is the random measurement error in measuring y ij . It is assumed that the ε ij s are independently distributed normal random variables with means 0 and variance σ 2 2i , t Li and t Ri are also assumed to be independently normally distributed with mean parameters η 0 , η 1 , 1 , 2 , t L and t R ; that is, η 0i = η 0 + b 0i for i = 1, . . . , n and similarly for η 1i , 1i , 2i , t Li and t Ri . b 0i indicates the individual variation. Our interest is to estimate both population parameters η 0 , η 1 , 1 , 2 , t L , t R and individual parameters η 0i , η 1i , 1i , 2i , t Li , t Ri . These parameters can be estimated by existing algorithms such as that of Lindstrom and Bates, 15 and implemented can be gained by using the Splus/R function nonlinear-mixed-effects (nlme). 14 
Relation between baseline RNA level and first decay rate
The first decay rate η 1 indicates the potency of antiviral therapies. 10, 16 By knowing the potency of a treatment for a particular patient at an early stage, we may be able to avoid giving that patient the less potent regimens. In addition, if we know that there is a correlation between the baseline RNA viral load and the rate of the first phase of decay (the indicator of treatment potency), we may be able to use the baseline viral load to determine whether a treatment regimen is potent enough for a particular patient. This correlation will help clinicians to select a treatment for their patients. Drugs may show different potencies for different patients being treated on the same regimen, because patients may absorb the drug differently, and patients' immune systems and other factors related to their responses to the drugs may be different.
Data analysis
We fit the viral load trajectory (viral dynamics) data by model (2), with response variables being the numbers of HIV-1 RNA copies per mL of plasma on a log 10 scale. We take 14 and 70 as initial values of t L and t R . Using the data within one of time intervals [0, 14], (14, 70] and (70, 336] to fit a simple linear model, and the estimated coefficients are taken as initial values for modeling (2) . The population estimates of the parameters of model .08). In a consequence, our population 3-segment curve is 5.066 − 0.127t when t ≤ 15; 3.341 − 0.012t when 15 < t ≤ 78; and 2.093 + 0.004t when t > 78. On average, the period from entry time to 15 days can be taken as the first stage and the period from 15 to 78 days can be taken as the second stage. The individual parameters η 0i , η 1i , 1i , 2i , t Li and t Ri are obtained by plugging in empirical Bayesian estimates for the random effects, and the individual curves are obtained consequently. Estimates of the variances of the random effects associated to η 0 , η 1 , 1 , 2 , t L and t R are 0.02, 0.05, 0.05, 0.004, 4.67 and 8.29, respectively.
We found that two patients' data were too irregular to be described by any of the three kinds of curves, but the patterns of changing viral load of 8, 26 and 12 patients followed the patterns shown in Figure 2 indicated by dotted and solid lines, respectively, and the observed data are indicated by plus signs. The first row of curves shows three-segment patterns like Figure 2(a) . The second row of curves shows two-segment patterns like Figure 2(b) . The third row of curves shows two-segment patterns like Figure 2(c) . For each patient, the estimated individual curve is much closer than the population curve to the observed values. This finding reflects the benefit of mixed-effects models in that the between-subject and within-subject variations are simultaneously accounted for. The population curve indicates that the viral load declines rapidly at the beginning of treatment, maintains a shallow decline from day 15 to day 78, then slightly rebounds. All individual curves are similar to the population curve at the beginning of treatment, though there are differences in magnitude. However, after 15 days the patterns of the individual curves are diversely different from the population curve. Even within a row, the slopes or change points for different patients have different magnitudes. The between-row difference is not only in magnitudes, but also in patterns. The virus did not develop resistance to drug in more than half the patients.
A scatter plot (Figure 4 ) of the baseline viral load and the first phase decay rates, η 1i , which are estimated using model (2) , shows that the relation between these two quantities is surprisingly unlike the traditional linear relation, being positive when log 10 (RNA) < 4.5 and negative when log 10 (RNA) > 4.5. The line in Figure 4 presents an intuitive impression of this relation. To further explore this finding, we separated patients into two groups on the basis of their baseline viral load being <4.5. The changing viral load patterns of those groups between initial treatment and day 14 are shown in Figure 5 . Some patients' viral loads dramatically declined (left plot) and this decline shows more promise of cure than does that of patients whose baseline viral load was >4.5 (right plot).
Discussion
A major obstacle to the treatment of HIV-infection with antiretroviral drugs is the development of drug resistance. To avoid this problem, we need to be able to estimate the time at which resistance will develop. To perform this estimation, we have developed an approach that assumes a segmental linear model with unknown change points for the viral load as indicated by log 10 (RNA). In this model, the first change point is the time at which the macrophages or other long-lived cells release HIV into the blood from lymphoid tissues 3 or the time at which patients develop drug resistance; the second change point is the time at which the virus develops resistance to the drugs.
For each patient in the ACTG 315 study, we knew the patient's viral load (copies of HIV-1 RNA per mL of blood) at various time points after treatment. Using these data and log transformation, we estimated that the first change point would overall occur 15 days after the start of treatment. The population estimates of the slopes of the three-segmental lines were −0.12, −0.012 and 0.004, respectively. The standard errors of these estimates are given by 0.046, 0.01 and 0.003. These estimates indicate that most patients had the similar slopes for the first segment but not the other segments. This observation may be explained by noting that, for some patients, the second segment was very short or barely noticeable, whereas for other patients, the second segment was long, and that although drug resistance developed in some patients, other patients did not develop or had barely noticeable drug resistance. The second and third segments of the changing viral load curves therefore showed considerable variation between individuals. Some patients' changing viral load patterns may not follow the two or three-segment pattern; a more complex form may be required to describe these patterns. Challenges of implementation and biological interpretation then arise.
Model (2) may be extended to a more general form, which contains covariates such as CD4+ cell counts. The study of the model is interesting and requires additional efforts, but it is beyond the scope of this paper.
